<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3007245701
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOSTAM 0.4 MG PROLONGED RELEASE TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TAMSULOSIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        28.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novartis Pharmaceutical Manufacturing LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novartis Pharmaceutical Manufacturing LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04CA02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What is NOSTAM</strong></p><p>&nbsp;</p><p>NOSTAM contains the active ingredient which belongs to the class of medicines called alpha adrenoceptor antagonists.</p><p>&nbsp;</p><p>Tamsulosin relaxes:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; smooth muscles in the prostate and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in urethra (the tube that carries urine to the outside).</p><p>This lets urine pass more readily and helps urination.</p><p>&nbsp;</p><p>Tamsulosin is intended for the treatment of men suffering from enlarged prostate (benign prostatic hyperplasia, BPH). This is a condition where the prostate gland is enlarged, which may make passing urine difficult. This may result in frequent need for urination or having to urinate at night, sensation of urge to urinate also after completion of urination, or a feeling of not completely emptying the bladder.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use NOSTAM if</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic (hypersensitive) to tamsulosin or to any of the other ingredients of NOSTAM,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe liver problems,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have fainting or dizziness when suddenly sitting or standing up.</p><p>&nbsp;</p><p><strong>Take special care with NOSTAM</strong></p><p>If you have severe kidney problems you should tell your doctor prior to the start of treatment.</p><p>&nbsp;</p><p>As with other medicines from this class dizziness may occur in isolated cases during the treatment with tamsulosin.</p><p>If you experience weakness or dizziness during the treatment with tamsulosin you should sit or lie down until the symptoms have gone.</p><p>&nbsp;</p><p>Before initiation of therapy with tamsulosin your doctor will examine you to rule out the possibility of other diseases that have the same symptoms as BPH. Before you start taking this medicine, you may even be referred to blood tests. Blood tests may be continued during treatment in order to monitor the action of the medicine.</p><p>&nbsp;</p><p>If you have been scheduled for eye surgery because of cloudiness of the lens (cataract)</p><p>please inform your eye specialist that you are using or have previously used tamsulosin. The specialist can then take appropriate precautions with respect to medication and surgical techniques to be used. Ask your doctor whether or not you should postpone or temporarily stop taking this medicine when undergoing eye surgery because of a cloudy lens.</p><p>&nbsp;</p><p><em>Children</em></p><p>Do not give this medicine to children or adolescents younger than 18 years of age because it does not work in this population.</p><p>&nbsp;</p><p><strong>Taking other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>In particular tell your doctor or pharmacist if you are taking:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to lower your blood pressure such as verapamil and diltiazem</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat HIV such as ritonavir or indinavir.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat a fungal infection such as ketoconazole or itraconazole</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other alpha-adrenoceptor antagonists such as doxazosin, indoramin, prazosin or alfuzosin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythromycin, an antibiotic used to treat infections</p><p><strong>Taking NOSTAM with food and drink</strong></p><p>Tamsulosin may be taken independently of meals.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Tamsulosin is not indicated for use in women.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>No studies on the effect on ability to drive and use machines have been performed. However, you have to take into consideration that drowsiness, blurred vision, dizziness and fainting may occur. If you feel weakness or dizziness, do not drive or operate machinery.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of NOSTAM</strong></p><p>NOSTAM contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take NOSTAM exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The usual dose is one tablet per day.</p><p>You can take NOSTAM with or without food. The tablet should be swallowed whole; it should not be crushed or chewed.</p><p>&nbsp;</p><p><strong>If you take more NOSTAM than you should</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call your doctor or pharmacist or go to the nearest hospital immediately</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take this patient information leaflet and any remaining tablets with you.</p><p>If you take more NOSTAM tablets than you should you may experience dizziness or fainting and headache.</p><p>&nbsp;</p><p><strong>If you forget to take NOSTAM</strong></p><p>You may take your tablet later the same day if you have forgotten to take it earlier.</p><p>If you have missed a day, just continue to take your daily tablet from the next day. Do not take a double dose to make up for a missed dose.</p><p>&nbsp;</p><p><strong>If you stop taking NOSTAM</strong></p><p>If you stop taking NOSTAM, your original complaints may return. Therefore, take NOSTAM for as long as your doctor prescribes, even if your complaints have already disappeared.</p><p>Always consult your doctor, if you consider stopping taking the medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, NOSTAM may cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Consult your doctor immediately if you notice any of the following side effects (you may experience an allergic reaction).</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bullous skin eruption (urticaria),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the feet, hands, lips, tongue or throat with breathing problems</p><p>&nbsp;</p><p><strong>If you experience weakness or dizziness while taking tamsulosin you should immediately sit or lie down until the problems resolve.</strong></p><p>&nbsp;</p><p><strong>Common</strong> (affects 1 to 10 out of 100 patients):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensation of dizziness,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ejaculation disorder (the ejaculation volume is reduced or absent).</p><p>&nbsp;</p><p><strong>Uncommon</strong> (affects 1 to 10 out of 1,000 patients):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast or uneven heartbeat (palpitations),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a fall in blood pressure on standing up, which causes dizziness, light-headedness or fainting,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny or stuffy nose,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick or vomiting,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea or constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (skin rash, itchy or inflamed skin),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of weakness.</p><p>&nbsp;</p><p><strong>Rare</strong> (affects 1 to 10 out of 10,000 patients):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting (syncope)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bullous skin eruption (urticaria), accompanied by swelling of the feet, hands, lips, tongue or throat with breathing problems. In such a case, consult your doctor immediately.</p><p>&nbsp;</p><p><strong>Very rare</strong> (affects less than 1 out of 10,000 patients):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persistent painful erection (priapism), usually unrelated to sexual activity,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe condition with blistering on the skin, mouth, eyes and on genitals (Stevens-Johnson syndrome).</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart rhythm, fast heart beat,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breathing,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, visual impairment,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeds,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, skin inflammation with blistering (erythema multiforme, exfoliative dermatitis).</p><p>&nbsp;</p><p>As with other medicines of this type (alpha adrenoceptor antagonists), also tamsulosin may cause drowsiness, blurred vision, dry mouth or oedema.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Do not use NOSTAM after the expiry date which is stated on the packaging after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30 &deg; C.</p><p>&nbsp;</p><p>Store in the original package.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is 0.4 mg of tamsulosin hydrochloride.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: microcrystalline cellulose, hydroxypropyl cellulose, lactose monohydrate,&nbsp; polyethylene oxide, butylhydroxytoluene, magnesium stearate, colloidal anhydrous silicon dioxide</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet film-coating: hypromellose, hydroxypropyl cellulose, macrogol 400, titanium oxide (E171), talc, quinoline yellow (E104), carmine (E120), iron oxide, black (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Round, biconvex, brown film-coated tablet with debossed “0.4” on one side and “SZ” on the other side.

NOSTAM tablets are packed in aluminium blisters: 10, 14, 20, 28, 30, 50, 56, 60, 80, 90, 100 and 200 prolonged-release tablets.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Marketing Authorisation Holder</strong></p><p>Sandoz GmbH</p><p>6250 Kundl</p><p>Austria</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Lek Pharmaceuticals d.d.</p><p>Verov&scaron;kova 57</p><p>1526 Ljubljana</p><p>Slovenia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                june 2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو نوستام</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي نوستام على المادة الفعالة التي تنتمي إلى فئة الأدوية التي تُسمَّى مضادات مستقبلات الألفا الأدرينالية.</p><p dir="RTL">يؤدي تامسولوسين إلى إرخاء:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العضلات الملساء في البروستاتا و</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الإحليل (القناة التي تحمل البول إلى خارج الجسم).</p><p dir="RTL">هذا يجعل البول يمر بسهولة أكبر ويساعد على التبول.</p><p dir="RTL">يُستعمَل تامسولوسين لعلاج الرجال الذين يعانون من تضخم البروستاتا (فرط تنسج البروستاتا الحميد، BPH). وهي حالة يحدث فيها تضخم لغدة البروستاتا، مما يجعل التبول صعباً. وهذا قد يؤدي إلى تكرار الرغبة في التبول أو الاحتياج إلى التبول أثناء الليل، أو الإحساس بالرغبة في التبول أيضاً بعد الانتهاء من التبول، أو الإحساس بعدم الإفراغ الكامل للمثانة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك أرجية (حساسية مفرطة) تجاه تامسولوسين، أو تجاه أي من المكونات الأخرى في نوستام.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل شديدة في الكبد،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الإغماء أو الدوخة عند النهوض فجأة إلى وضع الجلوس أو إلى وضع الوقوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب توخي الحذر الخاص مع نوستام</strong></p><p dir="RTL">إذا كانت لديك مشاكل شديدة في الكلى يجب أن تخبر طبيبك قبل البدء في استعمال العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شأنه شأن الأدوية الأخرى من هذه الفئة، قد تحدث دوخة في حالات منعزلة أثناء استعمال تامسولوسين.</p><p dir="RTL">إذا حدث لديك ضعف أو دوخة أثناء استعمال تامسولوسين يجب أن تجلس أو تستلقي إلى أن تزول الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل بدء العلاج باستعمال تامسولوسين سيقوم طبيبك بفحصك لاستبعاد إمكانية وجود أمراض أخرى تعطي نفس الأعراض التي يعطيها مرض BPH. قبل أن تبدأ في أخذ هذا الدواء، قد يُطلَب منك إجراء اختبارات للدم. قد يستمر إجراء اختبارات الدم أثناء العلاج لمراقبة مفعول الدواء.</p><p dir="RTL">إذا كان من المقرر أن تُجرَى لك عملية جراحية في العين بسبب وجود عتامة في العدسة (كتاركتا) برجاء أن تخبر أخصائي العيون بأنك تستعمل حالياً أو سبق لك أن استعملت تامسولوسين. عندئذ سيتخذ الأخصائي الاحتياجات اللازمة بشأن الأدوية والتقنية الجراحية التي يجب استخدامها. اسأل طبيبك عما إذا يمكنك أن تؤجل أو توقف مؤقتاً استعمال هذا الدواء عند إجراء عملية جراحية في العين بسبب وجود عتامة في العدسة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الأطفال</em></p><p dir="RTL">لا ينبغي إعطاء هذا الدواء للأطفال أو المراهقين تحت 18 سنة من العمر لأنه غير فعال في هذه الفئة من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استعمال أدوية أخرى</strong></p><p dir="RTL">برجاء أن تخبر طبيبك أو الصيدلي إذا كنت تستعمل حالياً أو إذا كنت قد استعملت منذ وقت قصير أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها بدون تذكرة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بصفة خاصة أخبر طبيبك أو الصيدلي إذا كنت تستعمل:</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لخفض ضغط الدم مثل فيراباميل ودلتيازيم</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج فيروس HIV مثل ريتونافير أو إندينافير.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج العدوى الفطرية مثل كيتوكونازول أو إيتراكونازول</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المضادة لمستقبلات الألفا الأدرينالية مثل دوكسازوسين، أو إندورامين، أو برازوسين، أو ألفوزوسين</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إريثرومايسين، وهو مضاد حيوي يُستعمَل لعلاج العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول نوستام مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول تامسولوسين بغض النظر عن مواعيد تناول الوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">تامسولوسين ليس له استعمال في النساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارة وتشغيل الآلات</strong></p><p dir="RTL">لم تُجرَ دراسات على تأثير الدواء على القدرة على قيادة السيارة، وتشغيل الآلات. لذلك يجب أن تضع في اعتبارك أنه من الممكن أن يحدث نعاس، وغشاوة في الإبصار، ودوخة، وإغماء. إذا شعرت بضعف أو دوخة، امتنع عن قيادة السيارة وتشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة عن بعض المكونات في نوستام</strong></p><p dir="RTL">يحتوي نوستام على لاكتوز. إذا كان طبيبك قد أخبرك بأن لديك عدم تحمُّل لبعض أنواع السكر، اتصل بطبيبك قبل استعمال هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التزم دائماً بتعليمات طبيبك عند استعمال نوستام. راجع مع طبيبك أو مع الصيدلي إذا كنت غير متأكد من طريقة الاستعمال. الجرعة المعتادة هي قرص واحد في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكنك أن تأخذ نوستام مع الطعام أو بدونه. يجب بلع القرص صحيحاً؛ ولا ينبغي سحقه أو مضغه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استعملت نوستام بأكثر مما ينبغي</strong></p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتصل بطبيبك أو الصيدلي أو اذهب فوراً إلى أقرب مستشفى</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ معك هذه النشرة الخاصة بالمعلومات للمريض، وأي أقراص متبقية.</p><p dir="RTL">إذا أخذت عدداً من أقراص نوستام أكثر مما ينبغي قد تحدث لديك دوخة أو إغماء وصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تأخذ نوستام</strong></p><p dir="RTL">يمكنك أن تأخذ قرصك في وقت لاحق في نفس اليوم إذا نسيت أن تأخذه في وقت مبكر.</p><p dir="RTL">إذا نسيت أن تأخذ الدواء في أحد الأيام، استمر في أخذ جرعتك اليومية ابتداء من اليوم التالي. لا تأخذ جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استعمال نوستام</strong></p><p dir="RTL">إذا توقفت عن استعمال نوستام، فإن شكواك الأصلية قد تعود مرة أخرى. لذلك يجب أن تأخذ نوستام للمدة التي يوصي بها طبيبك، حتى إذا كانت شكواك قد اختفت.</p><p dir="RTL">استشر دائماً طبيبك إذا فكرت في وقف استعمال الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى عن استعمال هذا المستحضر، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">شأنه شأن جميع الأدوية، فإن نوستام قد يؤدي إلى حدوث آثار جانبية، غير أنها لا تحدث لجميع الأشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استشر طبيبك فوراً إذا لاحظت أي من الآثار الجانبية التالية (فإنك قد تكون مُصاباً بتفاعل أرجي</strong><strong>).</strong></p><p dir="RTL">&ndash; طفح فقاعي في الجلد (أرتيكاريا)،</p><p dir="RTL">&ndash; تورم في القدمين، أو اليدين، أو الشفتين، أو اللسان، أو الحلق مع مشاكل في التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا حدث لديك ضعف أو دوخة أثناء استعمال تامسولوسين يجب أن تجلس أو تستلقي فوراً إلى أن تزول المشكلة</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (تُصيب 1 إلى 10 من بين 100 مريض):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في القذف (انخفاض حجم القذف أو انعدامه).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (تُصيب 1 إلى 10 من بين 1000 مريض):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسرع أو عدم انتظام ضربات القلب (خفقان)،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم عند النهوض إلى وضع الوقوف، مما يؤدي إلى حدوث دوخة، أو دوار، أو إغماء،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رشح من الأنف أو انسداد الأنف،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان أو قيء،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال أو إمساك</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات أرجية (طفح جلدي، أو حكة، أو التهاب جلدي)،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضعف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (تُصيب 1 إلى 10 من بين 10000 مريض):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء (فقدان الوعي)</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي فقاعي (أرتيكاريا)، مصحوب بتورم في القدمين، أو اليدين، أو الشفتين، أو اللسان، أو الحلق مع مشاكل في التنفس. في هذه الحالة، استشر طبيبك فوراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جداً</strong> (تُصيب أقل من 1 من بين 10000 مريض):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب مستمر ومؤلم (قسوح)، عادةً غير مرتبط بالنشاط الجنسي،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة شديدة مصحوبة ببثور على الجلد، والفم، والعينين، وعلى الأعضاء التناسلية (متلازمة ستيفنس جونسون).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معدل التكرار غير معروف</strong> (لا يمكن تقدير معدل التكرار من البيانات المتاحة):</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في النظم القلبي، تسرع ضربات القلب،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غشاوة في الإبصار، ضعف بصري،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف من الأنف،</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، التهاب جلدي مع بثور (حمامي متعددة الأشكال، التهاب جلدي تقشري).</p><p dir="RTL">&nbsp;</p><p dir="RTL">شأنه شأن الأدوية الأخرى من هذا النوع (مضادات مستقبلات الألفا الأدرينالية)، فإن تامسولوسين قد يؤدي إلى حدوث نعاس، أو غشاوة في الإبصار، أو جفاف الفم، أو وذمة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل نوستام بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد العلامة &ldquo;EXP&rdquo;. يُشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">يُحفَظ في درجة حرارة لا تزيد عن 30&deg;م.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفَظ في عبوته الأصلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي التخلُّص من الأدوية عبر مياه الصرف أو القمامة المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي يتم الاستغناء عنها. هذه الإجراءات ستساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ٠،٤ مجم تامسولوسين هيدروكلوريد.</p><p dir="RTL">&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صميم القرص: سيليلوز دقيق التبلور، هيدروكسي بروبيل سيليلوز، لاكتوز مونوهيدرات، أكسيد بولي إيثيلين، بيوتيل هيدروكسي تولوين، ستيارات ماغنسيوم، ثاني أكسيد السيليكون الغرواني اللامائي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف القرص: هيبروميلوز، هيدروكسي بروبيل سيليلوز، ماكروجول ٤٠٠، أكسيد التيتانيوم (E171)، تلك، أصفر كينولين (E104)، كارمين (E120)، أكسيد الحديد الأسود (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص مغلَّفة، مستديرة، ثنائية التحدب، بنية اللون، منقوش على أحد جانبيها العلامة &quot;0.4&quot; وعلى الجانب الآخر العلامة &quot;SZ&quot;.</p><p dir="RTL">أقراص نوستام معبأة في شرائط ألومنيوم تحتوي على: ١٠ و ١٤ و ٢٠ و ٢٨ و ٣٠ و ٥٠ و ٥٦ و ٦٠ و ٨٠ و ٩٠ و ١٠٠ و ٢٠٠ قرص ممتد الانطلاق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس بالضرورة أن تكون جميع أحجام العبوات متوافرة في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المالكة لحق التسويق</strong></p><p dir="RTL">ساندوز جي ام بي اج</p><p dir="RTL">&nbsp;٦٢٥٠ كوندل</p><p dir="RTL">&nbsp;النمسا</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">ليك فارماسوتيكلز د د،</p><p dir="RTL">فيروفسكوفا ٥٧</p><p dir="RTL">&nbsp;١٥٢٦ لوبليانا</p><p dir="RTL">سلوفينيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mycophenolate Mofetil500 mg Film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Film-coated tablets contains 500 mg of mycophenolate mofetil For a full list of excipients, see section  6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet:
Lavender coloured, film coated biconvex tablet plain on both the  sides.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mycophenolate Mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Mycophenolate Mofetil should be initiated and maintained by appropriately qualified transplant specialists.</p><p>&nbsp;</p><p><u>Use in renal transplant</u>:</p><p>&nbsp;</p><p><u>Adults</u>: oral Mycophenolate Mofetilshould be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1 g administered&nbsp;&nbsp; twice</p><p>&nbsp;</p><p>daily (2 g daily dose).</p><p>&nbsp;</p><p><u>Children and adolescents (aged 2 to 18 years)</u>: the recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g&nbsp; daily).</p><p>Mycophenolate mofetil 500 mg tablets should only be prescribed to patients with a body surface area greater than 1.5 m2, at a dose of 1 g twice daily (2 g daily dose). As some&nbsp; adverse&nbsp;</p><p>reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of&nbsp; reaction.</p><p>&nbsp;</p><p><u>Children (&lt; 2 years)</u>: there are limited safety and efficacy data in children below the age of 2 years. These are insufficient to make dosage recommendations and therefore use in this age group is not recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Use in cardiac transplant</u>:</p><p>&nbsp;</p><p><u>Adults</u>: oral Mycophenolate Mofetilshould be initiated within 5 days following transplantation. The recommended dose in cardiac transplant patients is 1.5 g administered twice daily (3 g daily dose).</p><p>&nbsp;</p><p><u>Children</u>: no data are available for pediatric cardiac transplant&nbsp; patients.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Use in hepatic transplant</u>:</p><p>&nbsp;</p><p><u>Adults: </u>Intravenous Mycophenolate should be administered for the first 4 days following hepatic transplant, with oral Mycophenolate Mofetilinitiated as soon after this as it can be tolerated. The recommended oral dose in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose).</p><p>&nbsp;</p><p><u>Children</u>: no data are available for pediatric hepatic transplant&nbsp; patients.</p><p>&nbsp;</p><p><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u>: the recommended dose of 1 g administered twice a day &nbsp;for renal transplant patients and 1.5 g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly.</p><p>&nbsp;</p><p><u>Use in renal impairment: </u>in renal transplant patients with severe chronic renal impairment (glomerular filtration rate &lt; <em>25 ml/min/1.73 m</em><em>2</em>), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided. These patients should also be carefully observed.</p><p>No dose adjustments are needed in patients experiencing delayed renal graft function post- operatively (see section 5.2). No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</p><p>&nbsp;</p><p><u>Use in severe hepatic impairment</u>: no dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. No data are available for cardiac transplant patients with severe hepatic parenchymal disease.</p><p>&nbsp;</p><p><u>Treatment during rejection episodes</u>: MPA (mycophenolic acid) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Mycophenolate Mofetilis not required. There is no basis for Mycophenolate Mofetildose adjustment following cardiac transplant rejection. No pharmacokinetic data are available during hepatic transplant&nbsp; rejection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity reactions to mycophenolate mofetil have been observed (see section 4.8). Therefore, Mycophenolate Mofetilis contraindicated in patients with a hypersensitivity to mycophenolate mofetil or mycophenolic acid.

Mycophenolate Mofetilis contraindicated in women who are breastfeeding (see section 4.6).

For information on use in pregnancy and contraceptive requirements see section  4.6.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>products, including mycophenolate, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. As general advice to minimize the risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection &nbsp;factor.</p><p>&nbsp;</p><p>Patients receiving mycophenolate should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.</p><p>&nbsp;</p><p>Patients treated with immunosuppressants, including mycophenolate mofetil, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). Among the opportunistic infections are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy&nbsp; (PML).</p><p>These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed&nbsp; patients with deteriorating renal function or neurological symptoms.</p><p>&nbsp;</p><p>Patients receiving mycophenolate should be monitored for neutropenia, which may be related to mycophenolate itself, concomitant medications, viral infections, or some combination of these causes. Patients taking mycophenolate should have complete blood counts&nbsp; weekly&nbsp; during the first month, twice monthly for the second and third months of treatment, then monthly through the first year. If neutropenia develops (absolute neutrophil count &lt; 1.3 x 103/&micro;l) it may be appropriate to interrupt or discontinue&nbsp; mycophenolate.</p><p>&nbsp;</p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressants. The mechanism for mycophenolate&nbsp; mofetil induced PRCA is unknown. PRCA may resolve with dose reduction&nbsp; or cessation of mycophenolate therapy. Changes to mycophenolate therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8).</p><p>&nbsp;</p><p>Patients should be advised that during treatment with mycophenolate vaccinations may be less effective, and the use of live attenuated vaccines should be avoided (see section&nbsp; 4.5).</p><p>Influenza vaccination may be of value. Prescribers should refer to national guidelines for influenza vaccination.</p><p>&nbsp;</p><p>Because mycophenolate has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation, mycophenolate should be administered with caution in patients with active serious digestive system disease.</p><p>&nbsp;</p><p>Mycophenolate is an IMPDH (inosine monophosphate dehydrogenase) inhibitor. On theoretical grounds, therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p><p>&nbsp;</p><p>It is recommended that mycophenolate not be administered concomitantly with azathioprine because such concomitant administration has not been&nbsp; studied.</p><p>&nbsp;</p><p>In view of the significant reduction in the AUC of MPA by colestyramine, caution should be used in the concomitant administration of mycophenolate with medicinal products that interfere with enterohepatic recirculation because of the potential to reduce the efficacy of mycophenolate.</p><p>&nbsp;</p><p>The risk: benefit of mycophenolate mofetil in combination with tacrolimus or sirolimus has not been established (see also section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p><u>Aciclovir</u>: higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovir in comparison to the administration of aciclovir alone.&nbsp;&nbsp; The&nbsp; changes in MPAG (the phenolic glucuronide of MPA) pharmacokinetics (MPAG increased by 8%) were minimal and are not considered clinically significant. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are aciclovir concentrations, the potential exists for mycophenolate mofetil and aciclovir, or its&nbsp;&nbsp; prodrugs,</p><p>e.g. valaciclovir, to compete for tubular secretion and further increases in concentrations of both substances may occur.</p><p>&nbsp;</p><p><u>Antacids with magnesium and aluminium hydroxides</u>: absorption of mycophenolate mofetil was decreased when administered with antacids.</p><p>&nbsp;</p><p><u>Proton pump inhibitors: </u>concomitant use of mycophenolate mofetil and proton pump inhibitors may significantly reduce MPA plasma&nbsp; concentrations.</p><p>&nbsp;</p><p><u>Colestyramine</u>: following single dose administration of 1.5 g of mycophenolate mofetil to normal healthy subjects pre-treated with 4 g TID (three times a day) of colestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4, and section &nbsp;5.2).</p><p>Caution should be used during concomitant administration because of the potential to reduce efficacy of mycophenolate mofetil.</p><p>&nbsp;</p><p><u>Medicinal products that interfere with enterohepatic circulation</u>: caution should be used with medicinal products that interfere with enterohepatic circulation because of their potential to reduce the efficacy of mycophenolate mofetil.</p><p>&nbsp;</p><p><u>Ciclosporin A: </u>ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate &nbsp;mofetil. In contrast, if concomitant ciclosporin treatment is stopped, an increase in MPA AUC of around 30% should be expected.</p><p>&nbsp;</p><p><u>Ganciclovir: </u>based on the results of a single dose administration study of recommended doses&nbsp;&nbsp; of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of mycophenolate (see section 4.2) and ganciclovir, it is anticipated that co- administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics is anticipated and mycophenolate dose adjustment is not required. In patients with renal impairment in which mycophenolate and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered the dose recommendations for ganciclovir should be observed and patients monitored carefully.</p><p>&nbsp;</p><p><u>Oral contraceptives</u>: the pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by coadministration of mycophenolate (see also section&nbsp; 5.2).</p><p>&nbsp;</p><p><u>Rifampicin: </u>in patients not also taking ciclosporin, concomitant administration of mycophenolate mofetil and rifampicin resulted in a decrease in MPA exposure (AUC0-12h)&nbsp;&nbsp; of&nbsp;18% to 70%. It is recommended to monitor MPA exposure levels and to adjust mycophenolate mofetil doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly.</p><p>&nbsp;</p><p><u>Sirolimus: </u>in renal transplant patients, concomitant administration of mycophenolate mofetil and CsA resulted in reduced MPA exposures by 30-50% compared with patients receiving the combination of sirolimus and similar doses of mycophenolate mofetil (see also section&nbsp;&nbsp; 4.4).</p><p>&nbsp;</p><p><u>Sevelamer: </u>decrease in MPA Cmax and AUC0-12 by 30% and 25%, respectively, were observed when mycophenolate mofetil was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection). It is recommended, however, to administer mycophenolate mofetil at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption of MPA. There is no data on mycophenolate mofetil with phosphate binders other than sevelamer.</p><p>&nbsp;</p><p><u>Trimethoprim/sulfamethoxazole:&nbsp; </u>no effect on the bioavailability of MPA was observed.</p><p>&nbsp;</p><p><u>Norfloxacin and metronidazole: </u>in healthy volunteers, no significant interaction was observed when mycophenolate mofetil was concomitantly administered with norfloxacin and metronidazole separately. However, norfloxacin and metronidazole combined reduced the MPA exposure by approximately 30% following a single dose of mycophenolate &nbsp;mofetil.</p><p>&nbsp;</p><p><u>Ciprofloxacin and amoxicillin plus clavulanic acid: </u>Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal transplant recipients in the days immediately following commencement of oral ciprofloxacin or&nbsp; amoxicillin&nbsp; plus&nbsp; clavulanic&nbsp; acid. This effect tended to diminish with continued&nbsp; antibiotic&nbsp; use and to cease&nbsp; within&nbsp; a few&nbsp; days of their discontinuation. The change in predose level&nbsp; may&nbsp; not&nbsp; accurately&nbsp; represent&nbsp; changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during&nbsp; the combination&nbsp; and shortly&nbsp; after antibiotic treatment.</p><p>&nbsp;</p><p><u>Tacrolimus: </u>in hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by coadministration&nbsp; with tacrolimus. In contrast, there was an increase&nbsp; of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5&nbsp; g BID) were administered to patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by mycophenolate mofetil (see also section 4.4).</p><p>&nbsp;</p><p><u>Telmisartan</u></p><p>Concomitant administration of telmisartan and Lamucon resulted in an approximately 30% decrease of MPA concentrations. Telmisartan changes MPA&#39;s elimination by enhancing PPAR gamma (peroxisome proliferator-activated receptor gamma) expression, which in turn results in an enhanced UGT1A9 expression and activity. When comparing rates of transplant rejection, rates of graft loss or adverse event profiles between Lamucon patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic drug-drug interaction were seen.</p><p>&nbsp;</p><p><u>Other interactions: </u>co-administration of probenecid with mycophenolate mofetil in&nbsp; monkeys&nbsp;raises plasma AUC of MPAG by 3-fold. Thus, other substances known to undergo&nbsp; renal&nbsp; tubular secretion may compete with MPAG and thereby raise plasma concentrations of MPAG or the other substance undergoing tubular&nbsp; secretion.</p><p>&nbsp;</p><p><u>Live vaccines: </u>live vaccines should not be given to patients with an impaired immune response. The antibody response to other vaccines may be diminished (see also section&nbsp; 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>(Pregnancy&nbsp; Category D)</p><p>&nbsp;</p><p>It is recommended that mycophenolate therapy should not be initiated until a negative pregnancy test has been obtained. Effective contraception must be used before beginning mycophenolate therapy, during therapy, and for six weeks following discontinuation of&nbsp; therapy (see section 4.5). Patients should be instructed to consult their physician immediately should pregnancy occur.</p><p>&nbsp;</p><p>The use of mycophenolate is not recommended during pregnancy and should be reserved for cases where no more suitable alternative treatment is available. Mycophenolate&nbsp; should be&nbsp; used in pregnant women only if the potential benefit outweighs the potential risk to the foetus. There is limited data from the use of mycophenolate in pregnant women. However, congenital malformations including ear malformations, i.e. abnormally formed or absent external/middle ear, have been reported in children of patients exposed to mycophenolate in combination with other immunosuppressants during pregnancy. Cases of spontaneous abortions have been reported in patients exposed to mycophenolate mofetil<em>. </em>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>Mycophenolate mofetil has been shown to be excreted in the milk of lactating rats. It is not known whether this substance is excreted in human milk. Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, mycophenolate is contraindicated in nursing mothers (see section&nbsp; 4.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. The pharmacodynamic profile and the reported adverse reactions indicate that an effect is unlikely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>The following undesirable effects cover adverse reactions from clinical&nbsp; trials:</u></p><p>The principal adverse reactions&nbsp; associated&nbsp; with&nbsp; the administration&nbsp; of mycophenolate&nbsp; mofetil in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting and there is evidence of a higher frequency of certain types of infections (see section 4.4).</p><p><u>Malignancies:</u></p><p>Patients receiving immunosuppressive regimens involving combinations of medicinal&nbsp; products, including mycophenolate mofetil, are at increased risk of developing lymphomas&nbsp;&nbsp; and other malignancies, particularly of the skin (see section 4.4). Lymphoproliferative disease or lymphoma developed in 0.6% of patients receiving mycophenolate mofetil (2 g or 3 g&nbsp;&nbsp; daily) in combination with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year. Non-melanoma skin carcinomas occurred in 3.6% of patients; other types of malignancy occurred in 1.1% of patients. Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3 &nbsp;years.</p><p>&nbsp;</p><p><u>Opportunistic infections:</u></p><p>All transplant patients are at increased risk of opportunistic infections; the risk increased with total immunosuppressive load (see section 4.4). The most common opportunistic infections in patients receiving mycophenolate mofetil (2 g or 3 g daily) with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients&nbsp; followed</p><p>for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex. The proportion of patients with CMV viraemia/syndrome&nbsp; was 13.5%.</p><p>&nbsp;</p><p><u>Children and adolescents (aged 2 to 18 years):</u></p><p>The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600 mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1 g mycophenolate mofetil twice daily. However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6 years of age, when compared to adults:diarrhoea, sepsis, leucopenia, anaemia and&nbsp; infection.</p><p>&nbsp;</p><p><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u>:</p><p>&nbsp;</p><p>immunosuppression. Elderly patients receiving mycophenolate mofetil as part of a&nbsp; combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.</p><p>&nbsp;</p><p><u>Other adverse&nbsp; reactions:</u></p><p>&nbsp;</p><p>and in &ge;1/100 to &lt;1/10 of patients treated with mycophenolate mofetil in the controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients are listed in the following table.</p><p>Adverse Reactions, Probably or Possibly Related to Mycophenolate Mofetil, Reported in Patients Treated with mycophenolate mofetil in Renal, Cardiac and Hepatic Clinical Trials when Used in Combination&nbsp; with Ciclosporin&nbsp; and Corticosteroids</p><p><strong>&nbsp;</strong></p><p>Within the system organ classes, undesirable effects are listed under heading of frequency, using the following categories:</p><p>Very common (&ge;1/10) Common (&ge;1/100 to &lt;1/10) Uncommon (&ge;1/1,000 to &lt;1/100) Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000), not known (cannot be estimated from the available&nbsp; data)</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse drug reactions</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Infections and infestations</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p><p>&nbsp;</p><p>&nbsp;</p><p>Blood and lymphatic system disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Metabolism and nutrition</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis, rhinitis</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Skin cancer, benign neoplasm of skin Leucopenia, thrombocytopenia, anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very</p></td><td style="vertical-align:top"><p>Pancytopenia, leucocytosis</p><p>&nbsp;</p><p>-</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Acidosis, hyperkalaemia, hypokalaemia, hyperglycaemia, hypomagnesaemia, hypocalcaemia, hypercholesterolaemia, hyperlipidaemia, hypophosphataemia, hyperuricaemia, gout, anorexia</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Agitation, confusional state, depression, anxiety, thinking abnormal, insomnia</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Convulsion, hypertonia, tremor, somnolence, myasthenic syndrome, dizziness, headache, paraesthesia, dysgeusia</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Tachycardia</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Respiratory, thoracic and</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very common</p></td><td rowspan="2" style="vertical-align:top"><p>Hypotension, hypertension, vasodilatation</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>mediastinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very</p></td><td style="vertical-align:top"><p>Pleural effusion, dyspnoea, cough</p><p>&nbsp;</p><p>Vomiting, abdominal pain, diarrhoea,</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="8" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Hepatobiliary disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Musculoskeletal and connective tissue disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Renal and urinary disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>General disorders and administration site conditions</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Investigations</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage, peritonitis, ileus, colitis, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, stomatitis, constipation, dyspepsia, flatulence, eructation</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Hepatitis, jaundice, hyperbilirubinaemia</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Skin hypertrophy, rash, acne, alopecia,</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Renal impairment</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p>&nbsp;</p><p>&nbsp;</p><p>Very common</p></td><td style="vertical-align:top"><p>Oedema, pyrexia, chills, pain, malaise, asthenia,</p><p>&nbsp;</p><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased, blood creatinine increased, blood lactate</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dehydrogenase increased, blood urea increased, blood alkaline phosphatase increased, weight decreased</p></td></tr></tbody></table><p>Note: 501 (2 g mycophenolate mofetil daily), 289 (3 g mycophenolate mofetil daily) and 277 (2 g IV / 3 g oral mycophenolate mofetil daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.</p><p>&nbsp;</p><p><u>The following undesirable effects cover adverse reactions from post-marketing experience: </u>The types of adverse reactions reported during post-marketing with mycophenolate mofetil are similar to those seen in the controlled renal, cardiac and hepatic transplant &nbsp;studies.</p><p>Additional adverse reactions reported during post-marketing are described below with the frequencies reported within brackets if known.</p><p>&nbsp;</p><p><u>Gastrointestinal</u>: gingival hyperplasia (&ge;1/100 to &lt;1/10), colitis including cytomegalovirus colitis (&ge;1/100 to &lt;1/10), pancreatitis(&ge;1/100&nbsp; to &lt;1/10), and intestinal villous atrophy.</p><p>&nbsp;</p><p><u>Disorders related to immunosuppression</u>: serious life-threatening infections including meningitis, endocarditis, tuberculosis and atypical mycobacterial infection. Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including mycophenolate mofetil.</p><p>Agranulocytosis (&ge;1/1000 to &lt;1/100) and neutropenia have been reported; therefore, regular monitoring of patients taking mycophenolate mofetil is advised (see section 4.4). There have been reports of aplastic anaemia and bone marrow depression in patients treated with mycophenolate mofetil, some of which have been&nbsp; fatal.</p><p>&nbsp;</p><p><u>Blood and lymphatic system disorder:</u></p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil (see section 4.4).</p><p>Isolated cases of abnormal neutrophil morphology, including the acquired Pelger-Huet anomaly, have been observed in patients treated with mycophenolate mofetil. These changes are not associated with impaired neutrophil function. These changes may suggest a &lsquo;left shift&rsquo; in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive mycophenolate mofetil.</p><p>&nbsp;</p><p><u>Hypersensitivity</u>: Hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction have been reported.</p><p>&nbsp;</p><p><u>Congenital disorders: </u>see further details in section&nbsp; 4.6.</p><p>&nbsp;</p><p><u>Respiratory, thoracic and mediastinal&nbsp; disorders:</u></p><p>&nbsp;</p><p>There have been isolated reports of interstitial lung disease and pulmonary fibrosis in patients treated with mycophenolate mofetil in combination with other immunosuppressants, some of which have been fatal.</p><p>&nbsp;</p><p>To reports any side&nbsp; effect(s):</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222,&nbsp; Exts 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000 E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>&nbsp;</p><p>Please contact the relevant competent&nbsp; authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience. In many of these cases, no adverse events were reported. In those overdose cases in which adverse events were reported, the events fall within the known safety profile of the medicinal product.</p><p>&nbsp;</p><p>It is expected that an overdose of mycophenolate mofetil could possibly result in oversuppression of the immune system and increase susceptibility to infections and bone marrow suppression (see section 4.4). If neutropenia develops, dosing with Mycophenolate Mofetilshould be interrupted or the dose reduced (see section&nbsp; 4.4).</p><p>&nbsp;</p><p>Haemodialysis would not be expected to remove clinically significant amounts of MPA or MPAG. Bile acid sequestrants, such as colestyramine, can remove MPA by decreasing the enterohepatic re-circulation of the drug (see section&nbsp; 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of action:</p><p>&nbsp;</p><p>Pharmacotherapeutic group: immunosuppressants, selective immunosuppressants, ATC code: L04AA06</p><p>&nbsp;</p><p>Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA. MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase,&nbsp; and</p><p>&nbsp;</p><p>therefore inhibits the <em>de novo </em>pathway of guanosine nucleotide synthesis without incorporation into DNA.</p><p>Because T- and B-lymphocytes are critically dependent for their proliferation on <em>de novo </em>synthesis of purines whereas other cell types can utilise salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:</p><p>&nbsp;</p><p>Following oral administration, mycophenolate mofetil undergoes rapid and extensive absorption and complete presystemic metabolism to the active metabolite, MPA. As evidenced by suppression of acute rejection following renal transplantation, the immunosuppressant activity of mycophenolate is correlated with MPA concentration. The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94% relative to IV mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC)&nbsp;&nbsp; of mycophenolate mofetil when administered at doses of 1.5 g BID to renal transplant patients. However, MPA Cmax was decreased by 40% in the presence of&nbsp; food.</p><p>Mycophenolate mofetil is not measurable systemically in plasma following oral administration.</p><p>&nbsp;</p><p>Distribution</p><p>&nbsp;</p><p>As a result of enterohepatic recirculation, secondary increases in plasma MPA concentration are usually observed at approximately 6 &ndash; 12 hours post-dose. A reduction in the AUC of MPA of approximately 40% is associated with the co-administration of colestyramine (4 g TID), indicating that there is a significant amount of enterohepatic&nbsp; recirculation.</p><p>&nbsp;</p><p>MPA at clinically relevant concentrations, is 97% bound to plasma albumin. Biotransformation</p><p>MPA is metabolised principally by glucuronyl transferase to form the phenolic glucuronide of MPA (MPAG), which is not pharmacologically&nbsp; active.</p><p>&nbsp;</p><p>&nbsp;</p><p>Elimination</p><p>&nbsp;</p><p>A negligible amount of substance is excreted as MPA (&lt; 1% of dose) in the urine. Orally administered radiolabelled mycophenolate mofetil results in complete recovery of the administered dose; with 93% of the administered dose recovered in the urine and 6% &nbsp;recovered in the faeces. Most (about 87%) of the administered dose is excreted in the urine as MPAG.</p><p>&nbsp;</p><p>At clinically encountered concentrations,&nbsp; MPA and MPAG are not removed by&nbsp; haemodialysis. However, at high MPAG plasma concentrations (&gt; 100 &micro;g/ml), small amounts of MPAG are removed.</p><p>&nbsp;</p><p>In the early post-transplant period (&lt; 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 &ndash; 6 months&nbsp;&nbsp; post-transplant).</p><p>&nbsp;</p><p><u>Renal impairment</u>:</p><p>In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate &lt;25 ml/min/1.73 m2) were 28 &ndash;&nbsp;&nbsp; 75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment. However, the mean single dose MPAG AUC was 3 &ndash;&nbsp; &nbsp;6-fold</p><p>higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG. Multiple&nbsp; dosing of mycophenolate mofetil in patients with severe chronic renal impairment has not&nbsp;&nbsp; been studied. No data are available for cardiac or hepatic transplant patients with severe&nbsp;&nbsp; chronic renal impairment.</p><p>&nbsp;</p><p><u>Delayed renal graft function</u>:</p><p>In patients with delayed renal graft function post-transplant, mean MPA AUC (0&ndash;12h)&nbsp;&nbsp; was</p><p>&nbsp;</p><p>comparable to that seen in post-transplant patients without delayed graft function. Mean&nbsp;&nbsp; plasma MPAG AUC (0-12h) was 2 &ndash; 3-fold higher than in post-transplant patients without delayed graft function. There may be a transient increase in the free fraction and &nbsp;concentration&nbsp;</p><p>of plasma MPA in patients with delayed renal graft function. Dose adjustment of mycophenolate does not appear to be necessary.</p><p>&nbsp;</p><p><u>Hepatic impairment</u>:</p><p>In volunteers with alcoholic cirrhosis, hepatic MPA glucuronidation processes were relatively unaffected by hepatic parenchymal disease. Effects of hepatic disease on this process probably depend on the particular disease. However, hepatic disease with predominantly&nbsp; biliary</p><p>damage, such as primary biliary cirrhosis, may show a different&nbsp; effect.</p><p>&nbsp;</p><p><u>Children and adolescents (aged 2 to 18 years):</u></p><p>Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients given 600 mg/m2 mycophenolate mofetil orally twice daily. This dose achieved MPA AUC values similar to those seen in adult renal transplant patients receiving mycophenolate at a dose &nbsp;of</p><p>1&nbsp; g BID in the early and late posttransplant period. MPA AUC values across age groups were similar in the early and late posttransplant &nbsp;period.</p><p>&nbsp;</p><p><u>&nbsp;Elderly&nbsp; pati ents&nbsp; (&ge;&nbsp; 65&nbsp; years) </u>:</p><p>Pharmacokinetic behavior of mycophenolate mofetil in the elderly has not been formally evaluated.</p><p>&nbsp;</p><p><u>Oral contraceptives</u>:</p><p>The pharmacokinetics of oral contraceptives were unaffected by coadministration of mycophenolate (see also section 4.5). A study of the coadministration of mycophenolate (1 g bid) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.15 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of mycophenolate on the ovulation suppressing action of the oral contraceptives. Serum levels of LH, FSH and progesterone were not significantly affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In experimental models, mycophenolate mofetil was not tumourigenic. The highest dose&nbsp;&nbsp; tested in the animal carcinogenicity studies resulted in approximately 2 &ndash; 3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical&nbsp;&nbsp; dose of 2 g/day and 1.3 &ndash; 2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3 &nbsp;g/day.</p><p>&nbsp;</p><p>Two genotoxicity assays (<em>in vitro </em>mouse lymphoma assay and <em>in vivo </em>mouse bone marrow micronucleus test) showed a potential of mycophenolate mofetil to cause chromosomal aberrations. These effects can be related to the pharmacodynamic&nbsp; mode of action, i.e.</p><p>inhibition of nucleotide synthesis in sensitive cells. Other <em>in vitro </em>tests for detection of gene mutation did not demonstrate genotoxic activity.</p><p>&nbsp;</p><p>Mycophenolate mofetil had no effect on fertility of male rats at oral doses up to 20 mg/kg/day. The systemic exposure at this dose represents 2 to 3 times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3 &ndash; 2 times&nbsp;&nbsp; the</p><p>clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients. In&nbsp; a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity. The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the&nbsp;&nbsp; recommended clinical dose of 3 g/day for cardiac transplant patients. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent &nbsp;generation.</p><p>&nbsp;</p><p>In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats&nbsp;&nbsp; at 6 mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity. The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients.</p><p>&nbsp;</p><p>Refer to section 4.6 .</p><p>&nbsp;</p><p>The haematopoietic and lymphoid systems were the primary organs affected in toxicology studies conducted with mycophenolate mofetil in the rat, mouse, dog and monkey. These effects occurred at systemic exposure levels that are equivalent to or less than the clinical exposure at the recommended dose of 2 g/day for renal transplant recipients. Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended doses. Gastrointestinal and renal effects consistent with dehydration were also observed in the monkey at the highest dose (systemic exposure levels equivalent to or greater than clinical exposure). The nonclinical toxicity profile of mycophenolate&nbsp; mofetil appears to be consistent with adverse events observed in human&nbsp; clinical trials which now provide safety data of more relevance to the patient population (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core content:</p><p>Cellulose microcrystalline</p><p>&nbsp;</p><p>Povidone Talc</p><p>Magnesium stearate Croscarmellose sodium</p><p>&nbsp;</p><p>Coating content: Hypromellose Hydroxypropylcellulose Titanium dioxide (E171) Macrogol( 400);</p><p>Iron Oxide Black (E172) Iron Oxide Red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2	years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 C. Keep the blister in the outer carton in order to protect from light. This medicinal product does not require any special storage&nbsp; conditions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:line id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;z-index:251658240;
 mso-position-horizontal-relative:page' from="97.85pt,13.4pt" to="97.85pt,26.65pt"
 strokeweight=".77pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="2" height="20" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.gif" />PVC/PE/PVdC/Al blister</p><p>Pack sizes: 50, 150 <u>and 250 </u>film-coated&nbsp; tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, tablets should not be crushed.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HEXAL AG, Holzkirchen  , Germany.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08.2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>